Released: April 24, 2024

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Alcohol and Substance Use Disorders Research Program Research Program
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)

The FY24 Defense Appropriations Act provides funding for the Alcohol and Substance Use Disorders Research Program (ASUDRP) to support research of exceptional scientific merit in the area of alcohol, opioid and other substance use disorders research. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The ASUDRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 ASUDRP funding opportunity announcements for the following award mechanisms will be posted on the website. Pre-application and application deadlines will be available when the announcements are released.

The ASUDRP population of interest includes individuals with alcohol and other substance use disorders, including opioid use disorder, particularly when co-occurring with PTSD, TBI and/or other mental health conditions. With the goals to treat alcohol and other substance use disorders, and to improve treatment adherence, prevent relapse and reduce risk of misuse, the applications submitted to the FY24 ASUDRP must address the following focus areas:

  • New medication targets
  • Novel medications
  • Re-purposed medications
  • Vaccines and other immunotherapies
  • Drug-drug combinations
  • More potent, longer-acting formulations to counteract opioid (including fentanyl and its analogs) overdose

Award Mechanism Eligibility Key Mechanism Elements Funding
Consortium Award Investigators at all academic levels (or equivalent)
  • Supports a single operations center to solicit and provide oversight and management of basic research and clinical trials within the consortium.
  • Principal investigator (PI) will provide leadership to facilitate collaboration of multiple organizations and individuals with the goal of translating basic science knowledge into evidence-based treatments for alcohol and other substance use disorders.
  • Consortium management team of highly qualified, multidisciplinary subject matter experts should be led by a PI with strong collaborative leadership experience in managing a consortium
  • The consortium management core is encouraged to include individual(s) with lived experience as consultant(s) to the leadership team
  • Submission of a Letter of Intent is required prior to full application submission.
  • Estimated maximum funding of $3,525,000 for total costs (direct plus indirect costs).

  • Two option periods (FY25 - FY26) pending future appropriations totaling up to $4M each.

  • Maximum period of performance is years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final funding opportunity announcement that will be available for downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under Email Subscriptions on the eBRAP homepage at For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Public Affairs

Last updated Wednesday, April 24, 2024